Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine

Recruiting now · Phase 2

Conditions studied: Cancer

In brief

The "simple" analysis of the exome can determine somatic and constitutional mutations. The major challenge lies in the translation of sequencing data into clinically relevant information allowing the clinician to guide his decision-making A "complex" analysis of the exome would provide access to structural DNA data, concerning mutational signatures, tumor mutational load, analysis of large deletions, loss of heterozygosity as well as amplification of certain genes which may have an impact on the management of patients. No data available to date makes it possible to assess the clinical interest of the availability of its additional information resulting from a "complex" analysis compared to a "simple" analysis. The objective of the EXOMA2 study is to assess the proportion of patients for whom the proposed therapy is derived from its additional information (complex analysis) and would not have been possible with a classic exome analysis (simple analysis) . We hereby formulate the hypothesis that a "complex" analysis on a population presenting a metastatic or locally advanced disease treated early (from the 1st line of treatment) will make it possible to determine therapeutic indications which could not be discovered with a "simple" analysis.

Key facts

Study ID

NCT04614480

Run by

Centre Georges Francois Leclerc

People needed

7976

Starts

2020-08-25

Expected to finish

2032-09-02

Last updated by the study team

2025-09-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• Weight> 30 Kg
• Histological or cytological evidence of the diagnosis of a metastatic or locally advanced solid tumor
• Patient in 1st line of treatment for metastatic or locally advanced disease
• Tumor material available in sufficient and usable quantity for the analyzes required by the study
• Request for exome analysis to be carried out when initiating the 1st or 2nd line of treatment (line initiated at the time of inclusion)
• Life expectancy estimated to be probably ≥ 6 months.
• WHO ≤ 1
• Patient capable and willing to follow all study procedures in accordance with the protocol
• Patient having understood the purpose, risks and constraints of the study and having signed and dated the consent form
• Patient affiliated to the social security scheme.

You may not qualify if…

• Tumor material not available or biopsy not possible.
• Inability to take a blood test.
• Refusal of genetic analysis.
• Patient likely to progress within 3 months of inclusion in the study.
• History of HIV / HBV / HCV infection.
• Patient already included in the EXOMA or EXOMA2 study.
• Woman who is pregnant, may be, or is breastfeeding.
• Persons deprived of their liberty or under guardianship (including curatorship).

Where it is running

• Centre Oscar Lambret — Lille, France (enrolling)
• Centre Henri Baclesse — Caen, France (enrolling)
• CGFL — Dijon, France (enrolling)
• Institut JeanGodinot — Reims, France (enrolling)
• Centre Eugène Marquis — Rennes, France (enrolling)
• CHU François Mitterrand — Dijon, France (enrolling)
• CHRU Jean Minjoz — Besançon, France (enrolling)
• Institut Hospitalier Franco-Britannique — Levallois-Perret, France
• Institut Bergonie — Bordeaux, France
• CHU Amiens Picardie — Amiens, France
• CHU Nantes — Nantes, France
• Chu Poitiers — Poitiers, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.